Scarica l'app Stockscreener
1.17
1.27%
-0.015
Precedente Chiudi:
$1.185
Aprire:
$1.2295
Volume 24 ore:
108.90K
Relative Volume:
0.89
Capitalizzazione di mercato:
$17.61M
Reddito:
$321.50K
Utile/perdita netta:
$-7.24M
Rapporto P/E:
-0.6686
EPS:
-1.7498
Flusso di cassa netto:
$-5.72M
1 W Prestazione:
-7.87%
1M Prestazione:
-16.43%
6M Prestazione:
-56.18%
1 anno Prestazione:
-17.02%
Intervallo 1D:
$1.03
$1.2295
Intervallo di 1 settimana:
$1.03
$1.33
Portata 52W:
$1.03
$3.62
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
22211 WEST INTERSTATE-10, SAN ANTONIO
Confronta BIAF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.17 | 17.61M | 321.50K | -7.24M | -5.72M | -1.7498 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
bioAffinity Technologies stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 - Zenopa
bioAffinity Technologies Reports Strong Q3 Growth - TipRanks
bioAffinity Technologies stock hits 52-week low at $1.24 By Investing.com - Investing.com Canada
bioAffinity Technologies Inc (BIAF) Quarterly 10-Q Report - Quartz
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development - Zenopa
bioAffinity appoints new Chief Science Officer By Investing.com - Investing.com Canada
bioAffinity appoints new Chief Science Officer - Investing.com India
bioAffinity Technologies Appoints William Bauta, Ph.D., as Chief Science Officer - citybiz
BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer - TipRanks
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development | BIAF Stock News - StockTitan
J. Michael Edwards Named CFO at bioAffinity Technologies - MPO-mag
SA company sets the stage for Asian expansion - The Business Journals
bioAffinity’s CyPath Lung Test Now Available to U.S. Veterans - MPO-mag
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung - Zenopa
bioAffinity secures Japanese patent for lung health test By Investing.com - Investing.com South Africa
BIAFbioAffinity Technologies, Inc. Latest Stock News & Market Updates - StockTitan
bioAffinity secures Japanese patent for lung health test - Investing.com
bioAffinity Technologies Closes of $2.6 Million Registered Direct Offering & Concurrent Private Placement - citybiz
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
SEC Form 424B5 filed by bioAffinity Technologies Inc. - Quantisnow
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity Technologies Prices of $2.66 Million Registered Direct Offering & Concurrent Private Placement - citybiz
BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement - MarketWatch
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity VP contributes to new cytometry guidelines - Investing.com
bioAffinity VP contributes to new cytometry guidelines By Investing.com - Investing.com South Africa
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines - StockTitan
Lung cancer test speeds growth of San Antonio's bioAffinity - Head Topics
New lung cancer test uses phlegm, machine learning to make early diagnoses - San Antonio Express-News
SA biomed to expand military market under new CFO - The Business Journals
bioAffinity Technologies names J. Michael Edwards as CFO - Investing.com India
bioAffinity Technologies names J. Michael Edwards as CFO By Investing.com - Investing.com Australia
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer - citybiz
bioAffinity Technologies Welcomes Back CFO for Future Growth - TipRanks
bioAffinity Technologies Appoints J. Michael Edwards as Chief Financial Officer - TechBullion
bioAffinity Technologies makes phlegm lung cancer test widely available to Veterans - Mugglehead
Maxim Group Initiates Coverage of bioAffinity Technologies (BIAF) with Buy Recommendation - MSN
BioAffinity Technologies : Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test Form 8 K - Marketscreener.com
bioAffinity Technologies Expands Access to Lung Cancer Test - TipRanks
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test - StockTitan
bioAffinity Technologies secures shareholder nod for warrant exercise - Investing.com
bioAffinity Technologies secures shareholder nod for warrant exercise By Investing.com - Investing.com UK
bioAffinity Technologies (NASDAQ:BIAFW) Shares Up 9.3% - Defense World
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis - BioSpace
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):